Molecular Classification of Head and Neck Tumors Using cDNA Microarray Analysis to Detect Prognosis and Response to Therapy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to study the genetic profile of head and neck tumors and their relationship to treatment response and outcome
| Condition |
|---|
|
Head and Neck Neoplasms |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Molecular Classification of Head and Neck Tumors Using cDNA Microarray Analysis to Detect Prognosis and Response to Therapy |
- correlation of treatment response and prognosis (time to recurrence and survival) with genetic expression profile [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- identify a series of diagnostic markers for head and neck tumors and study the mechanism of action of these proteins [ Time Frame: variable ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
- Tumor specimens along with normal mucosa obtained at the time of surgery for biopsy or resection of primary or recurrent tumors of the head and neck
- blood, urine and sputum from patients participating in the tumor collection described above
| Estimated Enrollment: | 400 |
| Study Start Date: | May 2002 |
| Estimated Study Completion Date: | March 2015 |
| Estimated Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
Previous research by our group using genetic microarray analysis of HNSCC and normal keratinocytes has identified two distinct groups of genetic expression based on clustering patterns of a subgroup of genes. Clinical data was summarized for each group and overall, patient segregation by gene expression profiling was a better predictor of outcome than clinicopathological variables. Further analysis identified 375 genes that discriminate between the genotypic subtypes of HNSCC. Overall, our preliminary data has shown that the pattern of global gene expression in a HNSCC specimen can be used as a predictor of prognosis. We isolated subsets of genes showing the greatest patterns of divergence in gene expression. We have also identified 366 over-expressed and 246 underexpressed genes when comparing primary tumor to normal surgical margins and have identified a similar number of genes whose expression has changed when comparing primary tumor to lymph node metastasis. Combining these data sets we have identified genes which consistently increase or decrease expression during progression from normal tissue to primary tumor, and subsequently to metastatic node. We have selected several candidate genes for subsequent analysis using HNSCC tissue arrays. Through DNA microarray analysis, a more detailed knowledge of the malignant transformation process, and alterations with therapy, in these patients may be obtained. This study will seek to characterize genetic profiles on 200 patients and correlate this data with patient's clinical data. Ultimately it is hoped that tumor specific genetic abnormalities may be identified which could provide targets for treatment strategies such as gene therapy, immunotherapy, or other interventions.
Study Objectives:
To evaluate gene expression patterns in human head and neck squamous cell carcinoma and correlate this with treatment response, both surgical and non-surgical.
To identify a series of diagnostic markers in blood, urine and/or sputum for head and neck squamous cell carcinoma and study the mechanism of action of these proteins.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients with tumors of the head and neck who ar ehaving diagnostic biopsy or surgical resection of primary lesions or recurrences
Inclusion Criteria:
- actual or suspected malignant or non-malignant tumors of the head and neck
- planned biopsy and/or resection, or availability of paraffin embedded or stored frozen tumor tissue for non-genetic analysis
Exclusion Criteria:
- insufficient tissue available for both standard diagnostic evaluation and study specimen
Contacts and Locations| Contact: Catherine Sarta, RN | 718-920-7054 | csarta@montefiore.org |
| Contact: Richard V Smith, MD | 718-920-8488 | rsmith@montefiore.org |
| United States, New York | |
| Montefiore Medical Center | Recruiting |
| Bronx, New York, United States, 10467 | |
| Contact: Catherine Sarta, RN 718-920-7054 csarta@montefiore.org | |
| Contact: Richard V Smith, MD 718-920-4267 rsmith@montefore.org | |
| Principal Investigator: Richard V Smith, MD | |
| Sub-Investigator: Thomas Belbin, PhD | |
| Sub-Investigator: Marvin Fried, MD | |
| Sub-Investigator: Michael Prystowsky, MD | |
| Sub-Investigator: Margaret Brandwein-Gensler, MD | |
| Principal Investigator: Missak Haigentz, MD | |
| Sub-Investigator: Schiff Bradley, MD | |
| Sub-Investigator: Randall P Owen, MD | |
| Principal Investigator: | Richard V Smith | Montefiore Medical Center |
| Principal Investigator: | Thomas Belbin, PhD | Montefiore Medical Center |
More Information
No publications provided
| Responsible Party: | Richard V. Smith, MD, Montefiore Medical Center |
| ClinicalTrials.gov Identifier: | NCT00200486 History of Changes |
| Other Study ID Numbers: | 02-05-127E, NIH-R21-CA104402 |
| Study First Received: | September 12, 2005 |
| Last Updated: | June 27, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Montefiore Medical Center:
|
genetic microarray head and neck cancer |
Additional relevant MeSH terms:
|
Neoplasms Head and Neck Neoplasms Neoplasms by Site |
ClinicalTrials.gov processed this record on May 19, 2013